Gothenburg, Sweden – 17 October 2024 – Atley Solutions announces the launch of the Atley C100, the world’s first commercial module specifically designed for the manufacturing of At-211 (astatine-211) radiopharmaceuticals.
“This launch marks an important moment for the At-211 community,” said Milton Lönnroth, CEO of Atley Solutions. “The Atley C100 will support the development of more precise cancer treatments, helping researchers take a significant step from the lab to the clinic. Our focus has always been on enabling the development and commercialisation of therapies that can make a meaningful difference in patients’ lives. This technology is designed to make that a reality.”
One Integrated Platform for Purifying At-211 and Synthesising At-211 radiopharmaceuticals
The Atley C100 module can both purify At-211 from irradiated cyclotron targets and synthesise At-211-based radiopharmaceuticals in an automated process. As a platform technology, the Atley C100 can be used to develop and manufacture multiple different At-211 radiopharmaceuticals, each focused on different cancer indications. With its recent CE marking and CB certification, the Atley C100 is now available to researchers and drug developers worldwide, offering new possibilities in the field of targeted cancer therapy.
Addressing the Challenges of Making At-211-based Therapies a Reality
The Atley C100 addresses some of the key obstacles in At-211 radiopharmaceutical development, a field that has long faced constraints due to the lack of specialised manufacturing tools. By providing a platform for manufacturing these compounds, the module helps to connect scientific research with clinical application.
“Targeted Radionuclide Therapy (TRT) with At-211 represents a promising approach for treating metastatic cancers, with minimal impact on healthy tissue,” said Emma Aneheim, Founder and Chief Scientific Officer (CSO) at Atley Solutions. “As a researcher focused on At-211, I see the launch of the Atley C100 as a very important step towards realising the potential of At-211 radiopharmaceuticals.”
Enabling Coming Generations of Cancer Therapies
Atley Solutions is committed to making the development of At-211-based therapies more accessible. With the Atley C100, the company aims to provide researchers and clinicians with a solution to help them explore the potential of astatine-based therapies and translate research into clinical possibilities. The focus on precision and scalability supports a future where more personalised cancer treatments become a standard part of care.
Production of the first Atley C100 modules is underway, with first deliveries to leading research institutions and pharmaceutical partners expected in the second half of 2024.
